Japanese Journal of Clinical Oncology Advance Access published online on February 20, 2006
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyi234
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan
* To whom correspondence should be addressed. Background: There have been few randomized controlled clinical trials until now to determine the effectiveness of adjuvant treatments for pancreatic cancer, and the results reported so far are inconsistent. Methods: Patients with invasive ductal pancreatic cancer who underwent radical surgery with clear histological margins at 11 Japanese institutions were enrolled and randomly assigned to one of two groups: surgery-alone group (no further treatment after surgery) and the surgery + chemotherapy group [two courses of postoperative adjuvant systemic chemotherapy with cisplatin (80 mg/m2, Day 1) and 5-fluorouracil (500 mg/m2/day, Days 1-5)]. Patients with a positive resectional margin or with resected distant metastases were excluded from the trial in order to minimize the influence of residual cancer. Results: Between 1992 and 2000, 89 patients were randomized into the two arms of the trial (45 patients to the surgery + chemotherapy arm and 44 patients to the surgery-alone arm). Four patients in total were found to be ineligible (three in the surgery + chemotherapy group and one in the surgery-alone group). The baseline characteristics were comparable between the two groups. In the surgery + chemotherapy group, four patients did not receive the adjuvant treatment because of patient refusal. Toxicity was minor and acceptable among the eligible patients in the surgery + chemotherapy group. The estimated 5-year survival rates were 26.4% in the surgery + chemotherapy group and 14.9% in the surgery-alone group, and the median duration of survival was 12.5 months and 15.8 months, respectively. The recurrence rates at 5 years were 73.6 and 80.8%, respectively, in the surgery + chemotherapy and the surgery-alone groups. The differences in the survival and recurrence rates between the two groups were not statistically significant. Conclusions: Postoperative adjuvant chemotherapy using cisplatin and 5-fluorouracil was safe and well tolerated; however, no clear survival benefit could be demonstrated.
Received October 8, 2005
Accepted December 19, 2005
Original Article
A Multicenter Randomized Controlled Trial to Evaluate the Effect of Adjuvant Cisplatin and 5-Fluorouracil Therapy after Curative Resection in Cases of Pancreatic Cancer
Tomoo Kosuge 1 *,
Takahiro Kiuchi 2,
Kiyoshi Mukai 3,
Tadao Kakizoe 4,
and
for the Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP)
2 University Hospital Medical Information Network Center, the University of Tokyo Hospital, Tokyo, Japan
3 Department of Diagnostic Pathology, Tokyo Medical University, Tokyo, Japan
4 National Cancer Center, Tokyo, Japan
Tomoo Kosuge, E-mail: tkosuge{at}ncc.go.jp
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. NAKAMURA, J. WADA, H. SUZUKI, M. TANAKA, M. KATANO, and T. MORISAKI Long-term Outcome of Immunotherapy for Patients with Refractory Pancreatic Cancer Anticancer Res, March 1, 2009; 29(3): 831 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Ghaneh, E Costello, and J P Neoptolemos Biology and management of pancreatic cancer Postgrad. Med. J., September 1, 2008; 84(995): 478 - 497. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ghaneh, E. Costello, and J. P Neoptolemos Biology and management of pancreatic cancer Gut, August 1, 2007; 56(8): 1134 - 1152. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Oettle, S. Post, P. Neuhaus, K. Gellert, J. Langrehr, K. Ridwelski, H. Schramm, J. Fahlke, C. Zuelke, C. Burkart, et al. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial JAMA, January 17, 2007; 297(3): 267 - 277. [Abstract] [Full Text] [PDF]
|
|